Kodiak Sciences (KOD) to Release Quarterly Earnings on Thursday

Kodiak Sciences (NASDAQ:KOD) is expected to announce its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($1.02) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 26, 2026 at 4:00 PM ET.

Kodiak Sciences Stock Performance

Kodiak Sciences stock opened at $22.08 on Thursday. The stock has a 50-day simple moving average of $25.24 and a 200 day simple moving average of $21.03. The stock has a market capitalization of $1.17 billion, a P/E ratio of -5.36 and a beta of 2.61. Kodiak Sciences has a 52 week low of $1.92 and a 52 week high of $31.18.

Analyst Ratings Changes

A number of research firms have recently issued reports on KOD. UBS Group started coverage on Kodiak Sciences in a research report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $38.00 price target on shares of Kodiak Sciences in a research note on Tuesday, February 10th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Kodiak Sciences in a report on Thursday, January 22nd. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $28.29.

Institutional Investors Weigh In On Kodiak Sciences

A number of institutional investors have recently made changes to their positions in KOD. Braidwell LP acquired a new position in shares of Kodiak Sciences in the fourth quarter valued at approximately $57,955,000. RTW Investments LP bought a new position in shares of Kodiak Sciences during the fourth quarter worth approximately $41,603,000. Janus Henderson Group PLC acquired a new stake in Kodiak Sciences during the 4th quarter worth approximately $27,950,000. Goldman Sachs Group Inc. boosted its stake in Kodiak Sciences by 298.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,303,030 shares of the company’s stock valued at $36,433,000 after purchasing an additional 976,254 shares during the period. Finally, State Street Corp boosted its stake in Kodiak Sciences by 108.1% in the 4th quarter. State Street Corp now owns 1,732,015 shares of the company’s stock valued at $48,427,000 after purchasing an additional 899,572 shares during the period. Institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Company Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.